O. Davies

3.2k citations
44 papers · 676 · h-index 15

Impact in

  • Rheumatology top 2%
    • Rheumatoid Arthritis Research and Therapies
    • Spondyloarthritis Studies and Treatments
    • Systemic Lupus Erythematosus Research
  • Hematology top 5%
    • Autoimmune and Inflammatory Disorders Research

Papers in

  • Rheumatology 25
    • Rheumatoid Arthritis Research and Therapies 16
    • Spondyloarthritis Studies and Treatments 14
    • Systemic Lupus Erythematosus Research 6
  • Immunology 11
    • Psoriasis: Treatment and Pathogenesis 11
Co-authors
Robert Landewé (11 shared papers)Désirée van der Heijde (11 shared papers)Bengt Hoepken (10 shared papers)T. Nurminen (10 shared papers)Walter P. Maksymowych (7 shared papers)Lars Bauer (4 shared papers)Xenofon Baraliakos (5 shared papers)Martín Rudwaleit (5 shared papers)
Journals
Annals of the Rheumatic Diseases (13 papers)Arthritis Care & Research (3 papers)Journal of the American Academy of Dermatology (2 papers)Lara D. Veeken (2 papers)The Journal of Rheumatology (2 papers)
Partner nations
United KingdomUnited StatesGermany

In The Last Decade

O. Davies

39 papers receiving 644 citations

Peers

O. Davies
Comparison fields: 5 of 85
  • Rheumatology 541
  • Hematology 207
  • Immunology 283
  • Genetics 76
  • Ophthalmology 49
Replace Shelly Kafka with:
Shelly Kafka United States
Shannon O’Neill United States
Megha Rajasekhar United Kingdom
Birgitta S. Breur-Vriesendorp Netherlands
Ulrich Wesselmann Germany
Joost M. Meijer Netherlands
Philipp Kastner Australia
H P Brezinschek Austria
Chikashi Yoshida Japan
Joanita Monteiro United States
O. Davies relative to Shelly Kafka United States Shelly Kafka's profile →
Citations per field
00.5×2×3×4×4.9×
Shelly Kafka · 1×
Citations per year

Countries citing papers authored by O. Davies

Since Specialization
Citations

This map shows the geographic impact of O. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Davies more than expected).

Fields of papers citing papers by O. Davies

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Davies. The network helps show where O. Davies may publish in the future.

Co-authors

The 25 scholars most cited alongside O. Davies, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with O. Davies Line = papers co-authored together O. Davies links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
Annals of the Rheumatic Diseases ·Désirée van der Heijde, Xenofon Baraliakos, Kay‐Geert Hermann, Robert Landewé, Pedro Machado, Walter P. Maksymowych, O. Davies, Natasha de Peyrecave, Bengt Hoepken, Lars Bauer, T. Nurminen, Juergen Braun
201890
2
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
Lara D. Veeken ·Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P. Maksymowych, Martín Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J. Mease, Alan Kivitz, Jessica A. Walsh, O. Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
201773
3
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
Lara D. Veeken ·Ernest Choy, Frank McKenna, Jiří Vencovský, R. Valente, Niti Goel, B. VanLunen, O. Davies, Henry Stahl, Rieke Alten
201267
4
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
Arthritis Care & Research ·Martín Rudwaleit, James T. Rosenbaum, Robert Landewé, Helena Marzo‐Ortega, Joachim Sieper, D. van der Heijde, O. Davies, Holger Bartz, Bengt Hoepken, T. Nurminen, Atul Deodhar
201665
5
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
The Journal of Rheumatology ·Désirée van der Heijde, Edward Keystone, Jeffrey R. Curtis, Robert Landewé, Michael Schiff, Dinesh Khanna, Tore K Kvien, Lucian Ionescu, Leon Gervitz, O. Davies, K. Luijtens, Daniel E. Furst
201254
6
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Annals of the Rheumatic Diseases ·Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, O. Davies, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler
202047
7
Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial
The Journal of Rheumatology ·Edward Keystone, Jeffrey R. Curtis, Roy Fleischmann, Daniel E. Fürst, Dinesh Khanna, Josef S Smolen, Philip J. Mease, Michael Schiff, G. Coteur, O. Davies, Bernard Combe
201137
8
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
RMD Open ·Jürgen Braun, Xenofon Baraliakos, Kay‐Geert Hermann, Robert Landewé, Pedro Machado, Walter P. Maksymowych, O. Davies, Bengt Hoepken, T. Nurminen, C. Stach, Désirée van der Heijde
201729
9
A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’
Arthritis Research & Therapy ·Robert Landewé, T. Nurminen, O. Davies, Dominique Baeten
201821
10
COVID-19 Impact on the Future of Hospitality and Travel
Journal of Hospitality & Tourism Research ·Frederick J. DeMicco, Marvin J. Cetron, O. Davies, Jackie Guzman
202117
11
Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
Arthritis Care & Research ·Désirée van der Heijde, Atul Deodhar, Roy Fleischmann, Philip J. Mease, Martín Rudwaleit, T. Nurminen, O. Davies
201617
12
FRI0150 Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study
Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, Gianfranco Ferraccioli, Włodzimierz Samborski, Francis Bérenbaum, O. Davies, Willem Koetse, B. Bennett, Harald Burkhardt
201215
13
Hospitality 2010 : The Future of Hospitality and Travel
Medical Entomology and Zoology ·Marvin J. Cetron, Fred J. DeMicco, O. Davies
200515
14
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
British Journal of Dermatology ·Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk De Cuyper, O. Davies, Diamant Thaçi
202314
15
Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
Arthritis Care & Research ·Daniel E. Furst, Saeed Ahmed Shaikh, Maria Greenwald, B. Bennett, O. Davies, K. Luijtens, Fabienne Staelens, Willem Koetse, Philippe Bertin
201414
16
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Arthritis Research & Therapy ·Michael E. Weinblatt, Roy Fleischmann, Ronald van Vollenhoven, Paul Emery, T. Huizinga, Maurizio Cutolo, Désirée van der Heijde, Benjamin Duncan, O. Davies, K. Luijtens, Maxime Dougados
201512
17
Age- and sex-based variation in helminth infection of helmeted guineafowl (Numida meleagris) with comments on Swainson's spurfowl (Pternistis swainsonii) and Orange River francolin (Scleroptila levaillantoides)
South African Journal of Wildlife Research ·O. Davies, Kerstin Junker, Raymond Jansen, Timothy M. Crowe, Joop Boomker
200812
18
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
Rheumatology and Therapy ·Roy Fleischmann, Ronald van Vollenhoven, Jiří Vencovský, Rieke Alten, O. Davies, Irina Mountian, M. de Longueville, David Carter, Ernest Choy
201710
19
Evaluating the Foundation Phase: the outcomes of Foundation Phase pupils (Report 1)
ORCA Online Research @Cardiff (Cardiff University) ·O. Davies, Chris Taylor, Trisha Maynard, Mirain Rhys, Samuel Waldron, David Blackaby
20137
20
The marketing approach to purchasing
Long Range Planning ·O. Davies
19747

About O. Davies

O. Davies is a scholar working on Rheumatology, Immunology, Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 44 papers that have together received 676 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (16 papers), Spondyloarthritis Studies and Treatments (14 papers), Psoriasis: Treatment and Pathogenesis (11 papers), Chronic Lymphocytic Leukemia Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Systemic Lupus Erythematosus Research (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). The work is most often cited by research in Rheumatology (541 citations), Hematology (207 citations), Immunology (283 citations), Genetics (76 citations) and Ophthalmology (49 citations). O. Davies has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Robert Landewé, Désirée van der Heijde, Bengt Hoepken, T. Nurminen, Walter P. Maksymowych, Lars Bauer, Xenofon Baraliakos, Martín Rudwaleit, Atul Deodhar and Natasha de Peyrecave. Their work appears in journals such as Annals of the Rheumatic Diseases, Arthritis Care & Research, Journal of the American Academy of Dermatology, Lara D. Veeken and The Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shelly KafkaBreakdown of academic impact, for papers by Shannon O’NeillBreakdown of academic impact, for papers by Megha RajasekharBreakdown of academic impact, for papers by Birgitta S. Breur-VriesendorpBreakdown of academic impact, for papers by Ulrich WesselmannBreakdown of academic impact, for papers by Joost M. MeijerBreakdown of academic impact, for papers by Philipp KastnerBreakdown of academic impact, for papers by H P BrezinschekBreakdown of academic impact, for papers by Chikashi YoshidaBreakdown of academic impact, for papers by Joanita Monteiro